Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

(2016) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014

(2016) Sibylle H. Lob et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010–2013

(2016) Shio-Shin Jean et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis

(2015) Gowri Raman et al.   BMC INFECTIOUS DISEASES

A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens

(2015) Karen Bush   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The emerging threat of multidrug-resistant Gram-negative bacteria in urology

(2015) Hosam M. Zowawi et al.   Nature Reviews Urology

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

(2014) Timothy A. Blizzard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Clinical Outcomes of Enterobacteriaceae Infections Stratified by Carbapenem MICs

(2014) Twisha S. Patel et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Clinical relevance of the ESKAPE pathogens

(2013) Jack N Pendleton et al.   Expert Review of Anti-Infective Therapy

In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

(2012) Elizabeth B. Hirsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

(2012) L. S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY REVIEWS

Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis

(2012) Wouter C. Rottier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

(2011) Alison G. Freifeld et al.   CLINICAL INFECTIOUS DISEASES

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

(2011) Kalpana Gupta et al.   CLINICAL INFECTIOUS DISEASES

Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region

(2011) Po-Ren Hsueh et al.   JOURNAL OF INFECTION

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy

(2009) Alexandre P Zavascki et al.   Expert Review of Anti-Infective Therapy